Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147157 | 0.86 | CYP1A2 (0.39) | CYP1A2KMT2ACYP2D6 | |
| SCHEMBL30147144 | 0.83 | PREP (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL19979716 | 0.81 | ALDH1A1 (0.39) | CYP1A2TSHREPHA2KDREPHB4 | |
| SCHEMBL19979715 | 0.81 | ALDH1A1 (0.39) | CYP1A2TSHREPHA2KDREPHB4 | |
| SCHEMBL18078162 | 0.76 | SPHK2 (0.38) | ALDH1A1MEN1KMT2A | |
| SCHEMBL27420162 | 0.76 | KMT2A (0.47) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL30877536 | 0.76 | KMT2A (0.47) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL30812430 | 0.74 | OXTR (0.39) | HCRTR1TSHRHCRTR2ALDH1A1LMNA | |
| SCHEMBL19871014 | 0.73 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL19871010 | 0.73 | HCRTR1 (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | ALBIUS SCIENCES ALPHA PRIVATE LIMITED (SG) | 2024-10-03 | — | — | US | disclosed |
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022270628-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | 国立大学法人 大分大学 | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | RSU1, TSLP, HAVCR2 | CYP1A2 273/4885HCRTR1 255/4885TSHR 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.